Thyroid cancer is the most common endocrine malignancy with an estimated 43,800 new
cases to be diagnosed in 2022 and representing the 7th most common cancer in women …

Abstract Context The Afirma® GSC aids in risk stratifying indeterminate thyroid nodule
cytology (ITN). The 2018 GSC validation study (VS) reported a sensitivity (SN) of 91 …

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Molecular diagnostic testing has had a profound impact on the diagnosis and management
of thyroid nodules and thyroid cancer. Based on the tremendous expansion of knowledge of …

Thyroid cancer is the most common endocrine malignancy, with increasing incidence over
the past few decades. Fine needle aspiration (FNA) biopsy is the gold standard for …

Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules
(ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post …

Background Thyroid nodules are commonly faced by clinicians as palpable nodules or
incidentally identified on imaging. Nodules that are found to be suspicious by imaging can …

Background Evidence guiding the management of cytologically indeterminate thyroid
nodules with nondiagnostic (ND) or benign cytology on repeat fine‐needle aspiration (FNA) …

Molecular testing of indeterminate thyroid nodules has helped to reduce the burden of
diagnostic surgery, associated healthcare costs, and potential complications. Current …

Thyroid cancer surgery has evolved dramatically with advances in our understanding of the
biological behaviour of WDTC. Molecular profiling is shedding light on the subset that may …